Conference
Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC).
Authors
Lu J; Deng H; Tang R; Hsu C; Kindler HL; Fuchs CS; Gansert JL; Bray S; Suzuki SS; Loh E
Volume
29
Pagination
pp. 4049-4049
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2011
DOI
10.1200/jco.2011.29.15_suppl.4049
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X